Hutchison China Meditech Limited Total Voting Rights (6434Z)
31 May 2016 - 4:01PM
UK Regulatory
TIDMHCM
RNS Number : 6434Z
Hutchison China Meditech Limited
31 May 2016
Total Voting Rights
London: Tuesday, May 31, 2016: For information purposes,
Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM)
hereby notifies the market that as at May 31, 2016, the issued
share capital of Chi-Med consisted of 60,649,342 ordinary shares of
US$1.00 each, with each share carrying one right to vote and with
no shares held in treasury.
The above figure of 60,649,342 may be used by shareholders as
the denominator for the calculations by which they could determine
if they are required to notify their interest in, or a change to
their interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Rules and Transparency Rules.
For illustrative purposes only, the 60,649,342 ordinary shares
would be equivalent to 60,649,342 CREST depositary interests (each
equating to one ordinary share) which are traded on AIM or, if the
CREST depositary interests were converted in their entirety,
equivalent to 121,298,684 American depositary shares (each equating
to one-half of one ordinary share) which are traded on Nasdaq.
Ends
Contact
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe +44 7973 611 888 (Mobile)
Rogerson anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile)
bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile)
sduffy@bmccommunications.com
Investor Relations
Jillian Connell, The Trout Group +1 (646) 378 2956
jconnell@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
Notes to Editors
About Chi-Med
Chi-Med is a China-based, globally-focused healthcare group
which researches, develops, manufactures and sells pharmaceuticals
and health-related consumer products. Its Innovation Platform,
Hutchison MediPharma Limited, is focused on discovering, developing
and commercializing innovative therapeutics in oncology and
autoimmune diseases. Its pipeline of eight novel oral compounds for
cancer and inflammation is in development in North America, Europe,
Australia and Greater China.
Chi-Med!|s Commercial Platform manufactures, markets and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAASEDLEKEAF
(END) Dow Jones Newswires
May 31, 2016 02:01 ET (06:01 GMT)